Investigating The Cardiovascular Effects Of Celecoxib In The Presence Of Heart Failure

Abstract

Cardiovascular risk seems to be elevated with using cyclooxygenase-2 inhibitors, according to both observational studies and randomized trials. Neither the dosage of celecoxib nor the patient's cardiovascular health before to therapy could be adequately evaluated in previous placebo-controlled randomized trials. Our objective was to evaluate the risk of cardiovascular events associated with three different doses of celecoxib and to determine whether or not there was a correlation between preexisting cardiovascular risk and the drug's influence on cardiovascular events. Primary end goal was a composite of cardiovascular-related deaths, MIs, strokes, heart failure, and thromboembolic complications. The hazard ratio for the combined dosages studied was 1.6 (95% CI, 1.1 to 2.3) after 16 070 patient-years of follow-up. We found indications of dose- and risk-based cardiovascular differences in response to celecoxib.